Patients’ Characteristics
| UPN . | Age/Gender . | Isotype . | Previous Treatments . | Time Off Therapy to Vaccination (mo) . | Disease Status at Vaccination . |
|---|---|---|---|---|---|
| 14 | 60/M | IgAλ | HDS*, DEX + IFN-α | 3 | RC |
| 240 | 61/F | IgGλ | HDS*, DEX + IFN-α | 3 | RC |
| 453 | 63/F | IgGλ | CM*, DEX + IFN-α | 4 | 1R50 |
| 485 | 62/F | IgGλ | CM* | 8 | RC |
| 510 | 47/F | IgAκ | HDS*, IFN-α | 2 | RC |
| 522 | 53/M | IgGλ | CM* | 3 | 1R75 |
| 535 | 57/M | IgAκ | HDS*, IFN-α | 17 | RC |
| 637 | 54/M | IgAλ | HDS* | 4 | RC |
| 734 | 60/F | IgGκ | Mev*, DEX | 2 | 1R75 |
| 743 | 65/M | κ† | Mev*, DEX | 2 | RC |
| 749 | 64/F | IgGκ | Mev*, DEX | 2 | RC |
| 847 | 60/F | IgGλ | Mev*, DEX | 2 | RC |
| UPN . | Age/Gender . | Isotype . | Previous Treatments . | Time Off Therapy to Vaccination (mo) . | Disease Status at Vaccination . |
|---|---|---|---|---|---|
| 14 | 60/M | IgAλ | HDS*, DEX + IFN-α | 3 | RC |
| 240 | 61/F | IgGλ | HDS*, DEX + IFN-α | 3 | RC |
| 453 | 63/F | IgGλ | CM*, DEX + IFN-α | 4 | 1R50 |
| 485 | 62/F | IgGλ | CM* | 8 | RC |
| 510 | 47/F | IgAκ | HDS*, IFN-α | 2 | RC |
| 522 | 53/M | IgGλ | CM* | 3 | 1R75 |
| 535 | 57/M | IgAκ | HDS*, IFN-α | 17 | RC |
| 637 | 54/M | IgAλ | HDS* | 4 | RC |
| 734 | 60/F | IgGκ | Mev*, DEX | 2 | 1R75 |
| 743 | 65/M | κ† | Mev*, DEX | 2 | RC |
| 749 | 64/F | IgGκ | Mev*, DEX | 2 | RC |
| 847 | 60/F | IgGλ | Mev*, DEX | 2 | RC |
Abbreviations: CM, high-dose cyclophosphamide ×3, high-dose melphalan ×3; HDS, high-dose sequential chemotherapy; Mev, high-dose cyclophosphamide ×1, high-dose melphalan ×2/3; DEX, dexamethasone; IFN-α, interferon-α; RC, first complete remission; 1R75, first remission (75% reduction serum M protein level); 1R50, first partial remission (50% reduction).
These regimens are followed by PBPC infusion.
Light chain disease.